CRISPR Therapeutics AG

NASDAQ: CRSP · Real-Time Price · USD
59.72
0.90 (1.53%)
At close: Aug 15, 2025, 3:59 PM
59.75
0.05%
After-hours: Aug 15, 2025, 06:55 PM EDT

CRISPR Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
35M 371.21M 436K 913.08M
Cost of Revenue
110.25M 130.25M 110.25M 17.95M
Gross Profit
-75.25M 240.96M -109.81M 895.13M
Operating Income
-466.57M -222.54M -673.16M 373.53M
Interest Income
n/a n/a n/a n/a
Pretax Income
-362.67M -150.72M -650.5M 379.53M
Net Income
-366.25M -153.61M -650.17M 377.66M
Selling & General & Admin
72.98M 76.16M 102.46M 102.8M
Research & Development
320.65M 387.33M 461.64M 438.63M
Other Expenses
110.25M -1.21M -762K -1.88M
Operating Expenses
503.88M 462.29M 563.35M 539.55M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
501.57M 593.74M 673.6M 539.55M
Income Tax Expense
3.59M 2.89M -325K 1.87M
Shares Outstanding (Basic)
84.36M 79.22M 77.75M 75.95M
Shares Outstanding (Diluted)
84.36M 79.22M 77.75M 80.39M
EPS (Basic)
-4.34 -1.94 -8.36 4.97
EPS (Diluted)
-4.34 -1.94 -8.36 4.70
EBITDA
-447.31M -202.7M -648.99M 391.48M
EBIT
-466.57M -222.54M -673.16M 373.53M
Depreciation & Amortization
19.26M 19.84M 24.17M 17.95M